The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis. Patient-reported outcomes (PROs), which have become important for approval of new therapies, was also measured to determine whether pacritinib reduced patients’ symptom burden and helped them feel better.
Pacritinib therapy led to symptom improvement in myelofibrosis
26th June 2015
Hematology
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now